COMBAT MEDICAL
BRS
Non-muscle-invasive bladder cancer (NMIBC), the most prevalent type of bladder cancer, accounts for three quarters of bladder cancer diagnoses.
Clinicians have found that heating the chemotherapy drug mitomycin-C prior to using it for treatment may radically improve its efficacy. The findings, published in the International Journal of Hyperthermia, are the result of a four-and-a-half-year study by medics based at Comarcal Hospital, Monforte, Spain.
The COMBAT BRS system, an innovative and patented recirculation system for the delivery of Hyperthermic Intra-VEsical Chemotherapy (HIVEC™) in the treatment of non-muscle invasive bladder cancer (NMIBC). Designworks worked to incorporate the patented system into a compact usable package and to develop an engineered design ready for low-volume production.
Already in clinical use the COMBAT BRS system maximises the efficiency of the chemotherapy treatment, is a safe and effective technology. It harnesses the proven synergistic effects of chemo-hyperthermia to target NMIBC whilst remaining simple to integrate into current practice. It requires minimal additional resources for the healthcare provider whilst maximising outcomes for patients with this type of bladder cancer.
